DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1923)

Immune Checkpoint Inhibitors | Access & Reimbursement | Detailed, Expanded Analysis: Multi-indication (US)

Immune Checkpoint Inhibitors | Access & Reimbursement | Detailed, Expanded Analysis: Multi-indication (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Coming Soon – December 2019

MARKET OUTLOOK:

 Immune checkpoint inhibitors have revolutionized the treatment of multiple oncology indications, including non-small-cell lung cancer (NSCLC), malignant melanoma, and bladder cancer. As premium-priced immune checkpoint inhibitors gain label expansions for additional indications and approvals as part of combinatorial regimens, the high cost associated with these agents will continue to present significant challenges for payers. Developing a clear understanding of prescribing patterns and the reimbursement landscape for immune checkpoint inhibitors is critical to maximize commercial success.

QUESTIONS ANSWERED

  • What role do immune checkpoint inhibitors play in the treatment of oncology indications such as NSCLC, malignant melanoma, and bladder cancer?
  • What are the key driving forces and constraints that influence MCO reimbursement decisions for immune checkpoint inhibitors?
  • Do access and reimbursement challenges for these agents differ by indication?
  • How do payers prioritize diminishing budgets and control prescribing of immune checkpoints accordingly?
  • What are medical oncologists’ views on select emerging immune checkpoint inhibitors in late-phase development? Wh

GEOGRAPHY: United States

PRIMARY RESEARCH: Survey of 100 U.S. medical oncologists Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs)

KEY DRUGS COVERED: Keytruda, Opdivo, Yervoy, Tecentriq, Imfinzi, Bavencio

CONTENT HIGHLIGHTS Reimbursement and contracting Access and prescribing Special topics Opportunities and challenges for emerging therapies

Table of contents

  • Detailed, Expanded Analysis: Multi-indication (US)
    • Coming Soon
      • Coming Soon

Already a Client? Log in to access this report.

  • Pub Date: February 2019
  • Author(s): Grace Mitchell, M.Res
  • is a business insights analyst in the oncology team at Decision Resources Group. Ms. Mitchell previously worked as an analyst at financial PR firm, Tulchan Communications, where she provided news on the pharmaceutical sector from a commercial perspective. Prior to this, Ms. Mitchell was a project assistant within the consulting team at DRG-Abacus where she learnt about HEOR and market access. Ms. Mitchell obtained her Masters in Cancer Sciences from the University of Birmingham. The degree focused on the expression of immune checkpoints in DLBCL. She also holds a in Biomedical Science from the University of Reading.

Purchase Report

Recent reports:
You may also be interested in: